Similarly, a study on 233 Chinese pediatric LCH patients found that BRAF and MAP2K1 mutations were not independent prognostic factors, regardless of whether the patient received second‐line treatment or targeted therapy [25]. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.